A phase I/II trial of rituxan [rituximab] and BEAM [carmustine + cytarabine + etoposide + melphalan] high-dose chemotherapy and autologous peripheral blood progenitor transplant for indolent lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 13 Dec 2013
At a glance
- Drugs Rituximab (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
- Indications Lymphoma
- Focus Therapeutic Use
- 01 Sep 2011 Actual end date Sep 2009 added as reported by ClinicalTrials.gov.
- 01 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jan 2008 New trial record.